JP2014505696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505696A5 JP2014505696A5 JP2013551000A JP2013551000A JP2014505696A5 JP 2014505696 A5 JP2014505696 A5 JP 2014505696A5 JP 2013551000 A JP2013551000 A JP 2013551000A JP 2013551000 A JP2013551000 A JP 2013551000A JP 2014505696 A5 JP2014505696 A5 JP 2014505696A5
- Authority
- JP
- Japan
- Prior art keywords
- morpholin
- methyl
- indol
- purine
- purin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 40
- 150000003839 salts Chemical class 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 32
- 150000002431 hydrogen Chemical class 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- -1 amino, hydroxy, carboxy Chemical group 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000005977 Ethylene Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 235000011962 puddings Nutrition 0.000 claims description 6
- CBSLYDYRSSZKJQ-UHFFFAOYSA-N 4-(2-morpholin-4-yl-8-phenyl-7h-purin-6-yl)morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=CC=CC=3)C2=N1 CBSLYDYRSSZKJQ-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- BYPBFDASESWSQG-HUUCEWRRSA-N (3r)-4-[8-(1h-indol-4-yl)-2-[(3r)-3-methylmorpholin-4-yl]-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 BYPBFDASESWSQG-HUUCEWRRSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- RTASTCNILVYNIH-KBPBESRZSA-N (1s,4s)-5-[8-(1h-indol-4-yl)-2-morpholin-4-yl-7h-purin-6-yl]-2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C([C@]1(OC[C@]2([H])C1)[H])N2C(C=1N=C(NC=1N=1)C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 RTASTCNILVYNIH-KBPBESRZSA-N 0.000 claims description 2
- VKDGYMMHLINOOQ-HOTGVXAUSA-N (1s,4s)-5-[8-(1h-indol-6-yl)-2-morpholin-4-yl-7h-purin-6-yl]-2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C([C@]1(OC[C@]2([H])C1)[H])N2C(C=1N=C(NC=1N=1)C=2C=C3NC=CC3=CC=2)=NC=1N1CCOCC1 VKDGYMMHLINOOQ-HOTGVXAUSA-N 0.000 claims description 2
- WJLUFTVOQWSVGA-CVEARBPZSA-N (3r)-4-[6-(1h-indol-4-yl)-2-[(3s)-3-methylmorpholin-4-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(C=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 WJLUFTVOQWSVGA-CVEARBPZSA-N 0.000 claims description 2
- BEVPZSCSVBGHBS-CQSZACIVSA-N (3r)-4-[8-(1h-indol-4-yl)-2-morpholin-4-yl-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 BEVPZSCSVBGHBS-CQSZACIVSA-N 0.000 claims description 2
- YHBIGTGZWVBCGN-CQSZACIVSA-N (3r)-4-[8-(1h-indol-4-yl)-6-morpholin-4-yl-7h-purin-2-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 YHBIGTGZWVBCGN-CQSZACIVSA-N 0.000 claims description 2
- UOJYDROKRRUPFT-HUUCEWRRSA-N (3r)-4-[8-(1h-indol-6-yl)-2-[(3r)-3-methylmorpholin-4-yl]-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(N=C(N2)C=3C=C4NC=CC4=CC=3)C2=N1 UOJYDROKRRUPFT-HUUCEWRRSA-N 0.000 claims description 2
- GKWDEEDUAOXXQS-CQSZACIVSA-N (3r)-4-[8-(1h-indol-6-yl)-2-morpholin-4-yl-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=C3NC=CC3=CC=1)N2 GKWDEEDUAOXXQS-CQSZACIVSA-N 0.000 claims description 2
- KQHGRDFADPRLCV-HUUCEWRRSA-N (3r)-4-[8-(2,3-dihydro-1h-indol-4-yl)-2-[(3r)-3-methylmorpholin-4-yl]-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(N=C(N2)C=3C=4CCNC=4C=CC=3)C2=N1 KQHGRDFADPRLCV-HUUCEWRRSA-N 0.000 claims description 2
- KQHGRDFADPRLCV-CABCVRRESA-N (3r)-4-[8-(2,3-dihydro-1h-indol-4-yl)-2-[(3s)-3-methylmorpholin-4-yl]-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(N=C(N2)C=3C=4CCNC=4C=CC=3)C2=N1 KQHGRDFADPRLCV-CABCVRRESA-N 0.000 claims description 2
- YLOCTAWZZXJSJN-KBPBESRZSA-N (3s)-3-methyl-4-[2-[(3s)-3-methylmorpholin-4-yl]-8-(1h-pyrrolo[2,3-b]pyridin-4-yl)-7h-purin-6-yl]morpholine Chemical compound C[C@H]1COCCN1C1=NC(N2[C@H](COCC2)C)=C(N=C(N2)C=3C=4C=CNC=4N=CC=3)C2=N1 YLOCTAWZZXJSJN-KBPBESRZSA-N 0.000 claims description 2
- LYQJKASYVKVEEA-AWEZNQCLSA-N (3s)-4-[2-(4,4-difluoropiperidin-1-yl)-8-(1h-indol-4-yl)-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2CCC(F)(F)CC2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 LYQJKASYVKVEEA-AWEZNQCLSA-N 0.000 claims description 2
- BYPBFDASESWSQG-GJZGRUSLSA-N (3s)-4-[8-(1h-indol-4-yl)-2-[(3s)-3-methylmorpholin-4-yl]-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2[C@H](COCC2)C)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 BYPBFDASESWSQG-GJZGRUSLSA-N 0.000 claims description 2
- BEVPZSCSVBGHBS-AWEZNQCLSA-N (3s)-4-[8-(1h-indol-4-yl)-2-morpholin-4-yl-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 BEVPZSCSVBGHBS-AWEZNQCLSA-N 0.000 claims description 2
- YHBIGTGZWVBCGN-AWEZNQCLSA-N (3s)-4-[8-(1h-indol-4-yl)-6-morpholin-4-yl-7h-purin-2-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 YHBIGTGZWVBCGN-AWEZNQCLSA-N 0.000 claims description 2
- UOJYDROKRRUPFT-GJZGRUSLSA-N (3s)-4-[8-(1h-indol-6-yl)-2-[(3s)-3-methylmorpholin-4-yl]-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2[C@H](COCC2)C)=C(N=C(N2)C=3C=C4NC=CC4=CC=3)C2=N1 UOJYDROKRRUPFT-GJZGRUSLSA-N 0.000 claims description 2
- GKWDEEDUAOXXQS-AWEZNQCLSA-N (3s)-4-[8-(1h-indol-6-yl)-2-morpholin-4-yl-7h-purin-6-yl]-3-methylmorpholine Chemical compound C[C@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=C3NC=CC3=CC=1)N2 GKWDEEDUAOXXQS-AWEZNQCLSA-N 0.000 claims description 2
- ILDHZDODQYEWAJ-MLCCFXAWSA-N 1-[3-[6-[(3s)-3-methylmorpholin-4-yl]-2-morpholin-4-yl-7h-purin-8-yl]phenyl]ethanol Chemical compound CC(O)C1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2[C@H](COCC2)C)N2CCOCC2)=C1 ILDHZDODQYEWAJ-MLCCFXAWSA-N 0.000 claims description 2
- UEYSRNFLKQULSV-AWEZNQCLSA-N 1-[8-(1h-indol-4-yl)-6-[(3s)-3-methylmorpholin-4-yl]-7h-purin-2-yl]piperidin-4-ol Chemical compound C[C@H]1COCCN1C1=NC(N2CCC(O)CC2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 UEYSRNFLKQULSV-AWEZNQCLSA-N 0.000 claims description 2
- JGGFNICMQLLJTB-UHFFFAOYSA-N 2-(2,6-dimorpholin-4-yl-7H-purin-8-yl)phenol Chemical compound OC1=CC=CC=C1C1=NC2=C(N3CCOCC3)N=C(N3CCOCC3)N=C2N1 JGGFNICMQLLJTB-UHFFFAOYSA-N 0.000 claims description 2
- HNTBJDRLVQNBKM-ZDUSSCGKSA-N 2-methoxy-5-[6-[(3s)-3-methylmorpholin-4-yl]-2-morpholin-4-yl-7h-purin-8-yl]benzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC=C1C1=NC2=C(N3[C@H](COCC3)C)N=C(N3CCOCC3)N=C2N1 HNTBJDRLVQNBKM-ZDUSSCGKSA-N 0.000 claims description 2
- LHDDJVLSHMJNRL-UHFFFAOYSA-N 3-(2,4-dimorpholin-4-yl-7h-pyrrolo[2,3-d]pyrimidin-6-yl)phenol Chemical compound OC1=CC=CC(C=2NC3=NC(=NC(=C3C=2)N2CCOCC2)N2CCOCC2)=C1 LHDDJVLSHMJNRL-UHFFFAOYSA-N 0.000 claims description 2
- FMZONAXKIRVOKC-UHFFFAOYSA-N 3-(2,6-dimorpholin-4-yl-7h-purin-8-yl)aniline Chemical compound NC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 FMZONAXKIRVOKC-UHFFFAOYSA-N 0.000 claims description 2
- VFXYAIGDRFKLJB-UHFFFAOYSA-N 3-(2,6-dimorpholin-4-yl-7h-purin-8-yl)phenol Chemical compound OC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 VFXYAIGDRFKLJB-UHFFFAOYSA-N 0.000 claims description 2
- UOSMHXGISNKBLD-OKILXGFUSA-N 3-[2-[(2r,6s)-2,6-dimethylmorpholin-4-yl]-6-morpholin-4-yl-7h-purin-8-yl]aniline Chemical compound C1[C@@H](C)O[C@@H](C)CN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=C(N)C=CC=3)C2=N1 UOSMHXGISNKBLD-OKILXGFUSA-N 0.000 claims description 2
- VZMACCZUZHFZEC-OKILXGFUSA-N 3-[2-[(2r,6s)-2,6-dimethylmorpholin-4-yl]-6-morpholin-4-yl-7h-purin-8-yl]phenol Chemical compound C1[C@@H](C)O[C@@H](C)CN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=C(O)C=CC=3)C2=N1 VZMACCZUZHFZEC-OKILXGFUSA-N 0.000 claims description 2
- KRYOJFZBIQYOHN-UHFFFAOYSA-N 3-[8-(1h-indol-4-yl)-2-morpholin-4-yl-7h-purin-6-yl]-8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C1C(O2)CCC2CN1C(C=1N=C(NC=1N=1)C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 KRYOJFZBIQYOHN-UHFFFAOYSA-N 0.000 claims description 2
- HGVRBIGKHBXUFG-QQFBHYJXSA-N 3-[8-(1h-indol-4-yl)-6-[(3r)-3-methylmorpholin-4-yl]-7h-purin-2-yl]-8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C[C@@H]1COCCN1C1=NC(N2CC3CCC(O3)C2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 HGVRBIGKHBXUFG-QQFBHYJXSA-N 0.000 claims description 2
- HGVRBIGKHBXUFG-FHERZECASA-N 3-[8-(1h-indol-4-yl)-6-[(3s)-3-methylmorpholin-4-yl]-7h-purin-2-yl]-8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C[C@H]1COCCN1C1=NC(N2CC3CCC(O3)C2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 HGVRBIGKHBXUFG-FHERZECASA-N 0.000 claims description 2
- DVPYIFZQYGTELJ-NNGSBXSVSA-N 3-[8-(1h-indol-6-yl)-6-[(3s)-3-methylmorpholin-4-yl]-7h-purin-2-yl]-8-oxa-3-azabicyclo[3.2.1]octane Chemical compound C[C@H]1COCCN1C1=NC(N2CC3CCC(O3)C2)=NC2=C1N=C(C=1C=C3NC=CC3=CC=1)N2 DVPYIFZQYGTELJ-NNGSBXSVSA-N 0.000 claims description 2
- LQZSVKMDKITWSJ-UHFFFAOYSA-N 4-[2-morpholin-4-yl-8-(1h-pyrrolo[3,2-b]pyridin-6-yl)-7h-purin-6-yl]morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=C4NC=CC4=NC=3)C2=N1 LQZSVKMDKITWSJ-UHFFFAOYSA-N 0.000 claims description 2
- ZEKDZZGWTRXRNM-UHFFFAOYSA-N 4-[6-(1h-indol-4-yl)-2-morpholin-4-yl-7h-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(C=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 ZEKDZZGWTRXRNM-UHFFFAOYSA-N 0.000 claims description 2
- SJCXYQGBFKEGFT-UHFFFAOYSA-N 4-[8-(1h-indazol-4-yl)-2-morpholin-4-yl-7h-purin-6-yl]morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=4C=NNC=4C=CC=3)C2=N1 SJCXYQGBFKEGFT-UHFFFAOYSA-N 0.000 claims description 2
- KRXHAQBOIOEJDX-UHFFFAOYSA-N 4-[8-(1h-indol-4-yl)-2-(4-methoxypiperidin-1-yl)-7h-purin-6-yl]morpholine Chemical compound C1CC(OC)CCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 KRXHAQBOIOEJDX-UHFFFAOYSA-N 0.000 claims description 2
- VJJPFNTUJZFMLU-UHFFFAOYSA-N 4-[8-(1h-indol-4-yl)-2-morpholin-4-yl-7h-purin-6-yl]-3,3-dimethylmorpholine Chemical compound CC1(C)COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=3C=CNC=3C=CC=1)N2 VJJPFNTUJZFMLU-UHFFFAOYSA-N 0.000 claims description 2
- IEEZPCDISDDNHG-UHFFFAOYSA-N 4-[8-(1h-indol-4-yl)-2-morpholin-4-yl-7h-purin-6-yl]morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=4C=CNC=4C=CC=3)C2=N1 IEEZPCDISDDNHG-UHFFFAOYSA-N 0.000 claims description 2
- VYRPJNSRBPXZAM-UHFFFAOYSA-N 4-[8-(1h-indol-6-yl)-2-morpholin-4-yl-7h-purin-6-yl]-3,3-dimethylmorpholine Chemical compound CC1(C)COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=C3NC=CC3=CC=1)N2 VYRPJNSRBPXZAM-UHFFFAOYSA-N 0.000 claims description 2
- OYYVNOMYSQOASK-UHFFFAOYSA-N 4-[8-(1h-indol-6-yl)-2-morpholin-4-yl-7h-purin-6-yl]morpholine Chemical compound C1COCCN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C=C4NC=CC4=CC=3)C2=N1 OYYVNOMYSQOASK-UHFFFAOYSA-N 0.000 claims description 2
- RUNAXPMSDKPKIK-UHFFFAOYSA-N 4-[8-(2-methyl-1h-indol-4-yl)-2-morpholin-4-yl-7h-purin-6-yl]morpholine Chemical compound C1=CC=C2NC(C)=CC2=C1C(NC1=N2)=NC1=C(N1CCOCC1)N=C2N1CCOCC1 RUNAXPMSDKPKIK-UHFFFAOYSA-N 0.000 claims description 2
- HBEQHZQYKVYGEC-STQMWFEESA-N 5-[2,6-bis[(3s)-3-methylmorpholin-4-yl]-7h-purin-8-yl]-1,3-dihydrobenzimidazol-2-one Chemical compound C[C@H]1COCCN1C1=NC(N2[C@H](COCC2)C)=C(N=C(N2)C=3C=C4NC(=O)NC4=CC=3)C2=N1 HBEQHZQYKVYGEC-STQMWFEESA-N 0.000 claims description 2
- MUZINCWNYBPUBQ-UHFFFAOYSA-N 8-[8-(1h-indol-4-yl)-2-morpholin-4-yl-7h-purin-6-yl]-3-oxa-8-azabicyclo[3.2.1]octane Chemical compound C1CC2COCC1N2C(C=1N=C(NC=1N=1)C=2C=3C=CNC=3C=CC=2)=NC=1N1CCOCC1 MUZINCWNYBPUBQ-UHFFFAOYSA-N 0.000 claims description 2
- AWTMEHOJPLEHIB-UHFFFAOYSA-N 8-[8-(1h-indol-6-yl)-2-morpholin-4-yl-7h-purin-6-yl]-3-oxa-8-azabicyclo[3.2.1]octane Chemical compound C1CC2COCC1N2C(C=1N=C(NC=1N=1)C=2C=C3NC=CC3=CC=2)=NC=1N1CCOCC1 AWTMEHOJPLEHIB-UHFFFAOYSA-N 0.000 claims description 2
- MGDXERJAXBSHNC-GASCZTMLSA-N [2-[2-[(2r,6s)-2,6-dimethylmorpholin-4-yl]-6-morpholin-4-yl-7h-purin-8-yl]phenyl]methanol Chemical compound C1[C@@H](C)O[C@@H](C)CN1C1=NC(N2CCOCC2)=C(N=C(N2)C=3C(=CC=CC=3)CO)C2=N1 MGDXERJAXBSHNC-GASCZTMLSA-N 0.000 claims description 2
- CWQWCVCZQYDZSG-ZDUSSCGKSA-N [2-fluoro-5-[6-[(3s)-3-methylmorpholin-4-yl]-2-morpholin-4-yl-7h-purin-8-yl]phenyl]methanol Chemical compound C[C@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C=C(CO)C(F)=CC=1)N2 CWQWCVCZQYDZSG-ZDUSSCGKSA-N 0.000 claims description 2
- NNJBEJBNMSIGPU-UHFFFAOYSA-N [3-(2,6-dimorpholin-4-yl-7h-purin-8-yl)phenyl]methanamine Chemical compound NCC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 NNJBEJBNMSIGPU-UHFFFAOYSA-N 0.000 claims description 2
- HHASSGIDQRQXQL-UHFFFAOYSA-N [3-(2,6-dimorpholin-4-yl-7h-purin-8-yl)phenyl]methanol Chemical compound OCC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 HHASSGIDQRQXQL-UHFFFAOYSA-N 0.000 claims description 2
- MXVIMDXYEAFHOH-ZIAGYGMSSA-N [3-[2,6-bis[(3r)-3-methylmorpholin-4-yl]-7h-purin-8-yl]-4-fluorophenyl]methanol Chemical compound C[C@@H]1COCCN1C1=NC(N2[C@@H](COCC2)C)=C(N=C(N2)C=3C(=CC=C(CO)C=3)F)C2=N1 MXVIMDXYEAFHOH-ZIAGYGMSSA-N 0.000 claims description 2
- RQQODQBXZJNYJU-GJZGRUSLSA-N [3-[2,6-bis[(3s)-3-methylmorpholin-4-yl]-7h-purin-8-yl]-5-methoxyphenyl]methanol Chemical compound COC1=CC(CO)=CC(C=2NC3=NC(=NC(=C3N=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 RQQODQBXZJNYJU-GJZGRUSLSA-N 0.000 claims description 2
- JVNUUIKGGAZSOR-ZDUSSCGKSA-N [4-chloro-3-[6-[(3s)-3-methylmorpholin-4-yl]-2-morpholin-4-yl-7h-purin-8-yl]phenyl]methanol Chemical compound C[C@H]1COCCN1C1=NC(N2CCOCC2)=NC2=C1N=C(C=1C(=CC=C(CO)C=1)Cl)N2 JVNUUIKGGAZSOR-ZDUSSCGKSA-N 0.000 claims description 2
- SXNLIWCUBYOYCB-GJZGRUSLSA-N [5-[2,6-bis[(3s)-3-methylmorpholin-4-yl]-7h-purin-8-yl]-2-methoxyphenyl]methanol Chemical compound C1=C(CO)C(OC)=CC=C1C1=NC2=C(N3[C@H](COCC3)C)N=C(N3[C@H](COCC3)C)N=C2N1 SXNLIWCUBYOYCB-GJZGRUSLSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- IDDGBSMMVIQCFB-UHFFFAOYSA-N n-[3-(2,6-dimorpholin-4-yl-7h-purin-8-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 IDDGBSMMVIQCFB-UHFFFAOYSA-N 0.000 claims description 2
- OBWFZOFNDPVEAB-UHFFFAOYSA-N n-[3-(2,6-dimorpholin-4-yl-7h-purin-8-yl)phenyl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(C=2NC3=NC(=NC(=C3N=2)N2CCOCC2)N2CCOCC2)=C1 OBWFZOFNDPVEAB-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- UXJUBJNTKJPGOA-UHFFFAOYSA-N [2-(2,6-dimorpholin-4-yl-7h-purin-8-yl)phenyl]methanol Chemical compound OCC1=CC=CC=C1C1=NC2=C(N3CCOCC3)N=C(N3CCOCC3)N=C2N1 UXJUBJNTKJPGOA-UHFFFAOYSA-N 0.000 claims 1
- 0 Cc(c(*)c1*)c(*)c(O)c1N Chemical compound Cc(c(*)c1*)c(*)c(O)c1N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161437956P | 2011-01-31 | 2011-01-31 | |
| US61/437,956 | 2011-01-31 | ||
| US201161552905P | 2011-10-28 | 2011-10-28 | |
| US61/552,905 | 2011-10-28 | ||
| PCT/IB2012/050428 WO2012104776A1 (en) | 2011-01-31 | 2012-01-30 | Novel heterocyclic derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014505696A JP2014505696A (ja) | 2014-03-06 |
| JP2014505696A5 true JP2014505696A5 (OSRAM) | 2015-03-05 |
| JP5963777B2 JP5963777B2 (ja) | 2016-08-03 |
Family
ID=45607319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551000A Expired - Fee Related JP5963777B2 (ja) | 2011-01-31 | 2012-01-30 | 新規ヘテロ環誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8987257B2 (OSRAM) |
| EP (1) | EP2670753B1 (OSRAM) |
| JP (1) | JP5963777B2 (OSRAM) |
| KR (1) | KR101928116B1 (OSRAM) |
| CN (1) | CN103476777B (OSRAM) |
| AP (1) | AP2013007043A0 (OSRAM) |
| AR (1) | AR085039A1 (OSRAM) |
| AU (1) | AU2012213080B2 (OSRAM) |
| BR (1) | BR112013019509A2 (OSRAM) |
| CA (1) | CA2825605C (OSRAM) |
| CL (1) | CL2013002177A1 (OSRAM) |
| CO (1) | CO6781507A2 (OSRAM) |
| CR (1) | CR20130369A (OSRAM) |
| EA (1) | EA025011B1 (OSRAM) |
| ES (1) | ES2611885T3 (OSRAM) |
| IL (1) | IL227664A0 (OSRAM) |
| MX (1) | MX343706B (OSRAM) |
| PE (1) | PE20140293A1 (OSRAM) |
| PH (1) | PH12013501600A1 (OSRAM) |
| PL (1) | PL2670753T3 (OSRAM) |
| PT (1) | PT2670753T (OSRAM) |
| SG (1) | SG192193A1 (OSRAM) |
| TW (1) | TW201309700A (OSRAM) |
| UY (1) | UY33883A (OSRAM) |
| WO (1) | WO2012104776A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| TW201309700A (zh) | 2011-01-31 | 2013-03-01 | Novartis Ag | 新穎雜環衍生物 |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| WO2013061305A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| WO2015053402A1 (ja) * | 2013-10-11 | 2015-04-16 | 国立大学法人東京医科歯科大学 | 脊髄小脳変性症を予防又は治療するための薬剤 |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| MX370099B (es) | 2014-03-26 | 2019-12-02 | Astex Therapeutics Ltd | Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer. |
| KR102479696B1 (ko) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Fgfr 억제제 및 igf1r 억제제의 조합물 |
| WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US20180214452A1 (en) | 2015-03-06 | 2018-08-02 | Korea Advanced Institute Of Science And Technology | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR |
| TWI689508B (zh) | 2015-03-30 | 2020-04-01 | 日商第一三共股份有限公司 | 可作爲ｐｉ３ｋ抑制劑之吡唑衍生物及其用途 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| KR102691777B1 (ko) | 2015-09-23 | 2024-08-02 | 얀센 파마슈티카 엔브이 | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 |
| CA2996857C (en) | 2015-09-23 | 2024-05-21 | Janssen Pharmaceutica Nv | Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer |
| KR102399639B1 (ko) | 2016-12-02 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
| CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| WO2021247841A1 (en) * | 2020-06-03 | 2021-12-09 | Yumanity Therapeutics, Inc. | Purines and methods of their use |
| US12405265B2 (en) * | 2020-06-12 | 2025-09-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Transient reporters and methods for base editing enrichment |
| KR20240133709A (ko) * | 2021-12-08 | 2024-09-04 | 키네타, 인크. | 퓨린 및 그의 사용 방법 |
| CN115181100A (zh) * | 2022-07-27 | 2022-10-14 | 广西大学 | 一种以嘌呤及吡咯并嘧啶母核的磺酰胺类小分子抑制剂 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864145A (en) * | 1959-06-02 | 1961-03-29 | Thomae Gmbh Dr K | Novel purines and a process for their manufacture |
| US3016378A (en) * | 1959-07-01 | 1962-01-09 | Thomae Gmbh Dr K | Amino-substituted purine derivatives |
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4323581A (en) | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| DE3752123T2 (de) | 1987-03-09 | 1998-05-14 | Kyowa Hakko Kogyo Kk | Derivate des physiologisch aktiven mittels k-252 |
| US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
| WO1989007105A1 (fr) | 1988-02-04 | 1989-08-10 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| AU2866992A (en) | 1991-10-10 | 1993-05-03 | Schering Corporation | 4'-(n-substituted-n-oxide)staurosporine derivatives |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| AU3064992A (en) | 1991-11-08 | 1993-06-07 | University Of Southern California | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| US5948898A (en) | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
| CZ236494A3 (en) * | 1992-04-03 | 1994-12-15 | Upjohn Co | Pharmaceutically active bicyclic-heterocyclic amines |
| US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
| US5756494A (en) | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
| CA2143335C (en) | 1992-08-31 | 2000-03-14 | Thierry Boon-Falleur | Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof |
| DE69331228D1 (en) | 1992-09-21 | 2002-01-10 | Kyowa Hakko Kogyo Kk | Heilmittel für thrombozytopenia |
| EP1238986B1 (en) | 1992-10-28 | 2008-06-25 | Genentech, Inc. | Use of Vascular endothelial cell growth factor antagonists |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| CA2167042A1 (en) | 1993-07-15 | 1995-01-26 | Kyle J. Lindstrom | Imidazo[4,5-c]pyridin-4-amines |
| US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| ATE456367T1 (de) | 1993-12-23 | 2010-02-15 | Lilly Co Eli | Proteinkinase c inhibitoren |
| US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| AU6888196A (en) | 1995-08-11 | 1997-03-12 | Yale University | Glycosylated indolocarbazole synthesis |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| EE03484B1 (et) | 1995-12-08 | 2001-08-15 | Janssen Pharmaceutica N.V. | Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine |
| KR100447918B1 (ko) | 1996-07-25 | 2005-09-28 | 동아제약주식회사 | 대장을포함한위장관보호작용을갖는플라본및플라바논화합물 |
| ES2256893T3 (es) | 1996-08-02 | 2006-07-16 | Genesense Technologies Inc. | Secuencias antisentido antitumorales dirigidas contra componentes r1 y r2 de la reductasa ribonucleica. |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| ES2253821T3 (es) | 1997-07-12 | 2006-06-01 | Cancer Research Technology Limited | Derivados de purina inhibidores de quinasa que depende de ciclina. |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| CA2314156C (en) | 1998-05-29 | 2010-05-25 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| US20030083242A1 (en) | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
| GEP20104998B (en) | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
| WO2001004125A1 (en) | 1999-07-13 | 2001-01-18 | Kyowa Hakko Kogyo Co., Ltd. | Staurosporin derivatives |
| EE05330B1 (et) | 1999-11-05 | 2010-08-16 | Astrazeneca Ab | Kinasoliini derivaadid kui VEGF-i inhibiitorid |
| US6573293B2 (en) | 2000-02-15 | 2003-06-03 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| AU5342701A (en) | 2000-04-12 | 2001-10-30 | Genaera Corp | A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group |
| AU7307101A (en) | 2000-06-30 | 2002-01-14 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| ES2302106T3 (es) | 2000-09-11 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina. |
| US6677450B2 (en) | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
| US6919183B2 (en) | 2001-01-16 | 2005-07-19 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| WO2002062826A1 (fr) | 2001-02-07 | 2002-08-15 | Vadim Viktorovich Novikov | Procede de fabrication des peptides |
| US20040186172A1 (en) | 2001-07-02 | 2004-09-23 | Houssam Ibrahim | Oxaliplatin active substance with a very low content of oxalic acid |
| KR100484504B1 (ko) | 2001-09-18 | 2005-04-20 | 학교법인 포항공과대학교 | 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물 |
| US20030134846A1 (en) | 2001-10-09 | 2003-07-17 | Schering Corporation | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
| AU2002316231A1 (en) | 2002-02-19 | 2003-09-29 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| JP4628678B2 (ja) | 2002-03-29 | 2011-02-09 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 置換ベンズアゾールおよびＲａｆキナーゼ阻害剤としてのそれらの使用 |
| US6727272B1 (en) | 2002-07-15 | 2004-04-27 | Unitech Pharmaceuticals, Inc. | Leflunomide analogs for treating rheumatoid arthritis |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| EP1587473A4 (en) | 2002-12-27 | 2008-08-13 | Novartis Vaccines & Diagnostic | THIOSEMICARBAZONE AS VIRUZIDES AND IMMUNOSTIMULATORS |
| ES2391770T3 (es) | 2003-01-21 | 2012-11-29 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos de triptantrina para la potenciación inmune |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
| WO2010002954A1 (en) * | 2008-07-02 | 2010-01-07 | Wyeth | (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| JP2012505881A (ja) | 2008-10-15 | 2012-03-08 | ギリアード サイエンシーズ， インコーポレイテッド | ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための３−ヒドロキナゾリン−４−オン誘導体 |
| JP5877064B2 (ja) * | 2008-11-11 | 2016-03-02 | エックスカバリー ホールディング カンパニー エルエルシー | ＰＩ３Ｋ／ｍＴＯＲキナーゼ阻害剤 |
| EP2470546B1 (en) | 2009-08-28 | 2013-07-24 | Takeda Pharmaceutical Company Limited | Hexahydrooxazinopteridine compounds for use as mtor inhibitors |
| MX2012005463A (es) | 2009-11-12 | 2012-09-12 | Hoffmann La Roche | Compuestos de purina n/9 sustituida, composiciones y metodos de uso. |
| BR112012011147A2 (pt) | 2009-11-12 | 2021-09-08 | F.Hoffmann-La Roche Ag | Composto, composição farmacêutica e uso de um composto. |
| WO2011078795A1 (en) | 2009-12-21 | 2011-06-30 | S*Bio Pte Ltd | Bridged morpholino substituted purines |
| AR083267A1 (es) | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
| TW201309700A (zh) | 2011-01-31 | 2013-03-01 | Novartis Ag | 新穎雜環衍生物 |
| CN103650345A (zh) | 2011-07-22 | 2014-03-19 | 辉达公司 | 部件分析系统及方法 |
| WO2013061305A1 (en) | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
-
2012
- 2012-01-30 TW TW101102924A patent/TW201309700A/zh unknown
- 2012-01-30 AP AP2013007043A patent/AP2013007043A0/xx unknown
- 2012-01-30 BR BR112013019509A patent/BR112013019509A2/pt not_active Application Discontinuation
- 2012-01-30 SG SG2013057492A patent/SG192193A1/en unknown
- 2012-01-30 PE PE2013001714A patent/PE20140293A1/es not_active Application Discontinuation
- 2012-01-30 AR ARP120100296A patent/AR085039A1/es not_active Application Discontinuation
- 2012-01-30 PT PT127041358T patent/PT2670753T/pt unknown
- 2012-01-30 PL PL12704135T patent/PL2670753T3/pl unknown
- 2012-01-30 KR KR1020137022750A patent/KR101928116B1/ko not_active Expired - Fee Related
- 2012-01-30 WO PCT/IB2012/050428 patent/WO2012104776A1/en not_active Ceased
- 2012-01-30 JP JP2013551000A patent/JP5963777B2/ja not_active Expired - Fee Related
- 2012-01-30 AU AU2012213080A patent/AU2012213080B2/en not_active Ceased
- 2012-01-30 EA EA201391106A patent/EA025011B1/ru not_active IP Right Cessation
- 2012-01-30 EP EP12704135.8A patent/EP2670753B1/en active Active
- 2012-01-30 CN CN201280014339.6A patent/CN103476777B/zh not_active Expired - Fee Related
- 2012-01-30 US US13/361,365 patent/US8987257B2/en not_active Expired - Fee Related
- 2012-01-30 CA CA2825605A patent/CA2825605C/en not_active Expired - Fee Related
- 2012-01-30 PH PH1/2013/501600A patent/PH12013501600A1/en unknown
- 2012-01-30 UY UY0001033883A patent/UY33883A/es not_active Application Discontinuation
- 2012-01-30 ES ES12704135.8T patent/ES2611885T3/es active Active
- 2012-01-30 MX MX2013008795A patent/MX343706B/es active IP Right Grant
-
2013
- 2013-07-25 IL IL227664A patent/IL227664A0/en unknown
- 2013-07-29 CO CO13179136A patent/CO6781507A2/es not_active Application Discontinuation
- 2013-07-30 CL CL2013002177A patent/CL2013002177A1/es unknown
- 2013-07-31 CR CR20130369A patent/CR20130369A/es unknown
-
2015
- 2015-03-11 US US14/644,953 patent/US9458163B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505696A5 (OSRAM) | ||
| JP6862495B2 (ja) | Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置 | |
| TWI784255B (zh) | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 | |
| CA2867918C (en) | Compounds and methods for kinase modulation, and indications therefor | |
| ES2985528T3 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades | |
| JP2014521725A5 (OSRAM) | ||
| AU2018350980B2 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors | |
| JP2013529196A5 (OSRAM) | ||
| JP5581390B2 (ja) | Ａｋｔ阻害剤 | |
| JP2020530496A5 (OSRAM) | ||
| JP2014505735A5 (OSRAM) | ||
| CN114599361A (zh) | Prmt5抑制剂的药物组合物 | |
| MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
| JP2014511893A5 (OSRAM) | ||
| EP2650293A8 (en) | [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof | |
| JP2020526549A5 (OSRAM) | ||
| US20220235048A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| JP2008517913A5 (OSRAM) | ||
| RU2014109748A (ru) | Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor | |
| RU2014131367A (ru) | Соединения тиенопиримидина | |
| IL303472A (en) | Alk-5 inhibitors and uses thereof | |
| JP2009525292A5 (OSRAM) | ||
| EP4634193A1 (en) | Substituted dihydropyrrolo[3, 4-d]pyrimidine compounds and their use in treating medical conditions | |
| RU2015120651A (ru) | Производные имидазопиридина | |
| SI2864328T1 (en) | Pharmaceutically active compounds |